par Berghuis, Bianca;Stapleton, Caragh;Sonsma, Anja A.C.M.;Hulst, Janic;de Haan, Gerrit Jan;Lindhout, Dick;Demurtas, Rita;Krause, Roland;Depondt, Chantal ;Kunz, Wolfram W.S.;Zara, Federico;Striano, Pasquale;Craig, John;Auce, Pauls;Marson, Anthony Guy;Stefansson, Hreinn;O'Brien, Terence John;Johnson, Margaret;Sills, Graeme;Wolking, Stefan;Lerche, Holger;Sisodiya, Sanjay;Sander, Ley J.W.;Cavalleri, Gianpiero;Koeleman, Bobby B.P.C.;McCormack, Mark
Référence Epilepsia Open, 4, 1, page (102-109)
Publication Publié, 2019-03-01
Référence Epilepsia Open, 4, 1, page (102-109)
Publication Publié, 2019-03-01
Article révisé par les pairs
Résumé : | Objective: To ascertain the clinical and genetic factors contributing to carbamazepine- and oxcarbazepine-induced hyponatremia (COIH), and to carbamazepine (CBZ) metabolism, in a retrospectively collected, cross-sectional cohort of people with epilepsy. Methods: We collected data on serum sodium levels and antiepileptic drug levels in people with epilepsy attending a tertiary epilepsy center while on treatment with CBZ or OXC. We defined hyponatremia as Na+ ≤134 mEq/L. We estimated the CBZ metabolic ratio defined as the log transformation of the ratio of metabolite CBZ-diol to unchanged drug precursor substrate as measured in serum. Results: Clinical and genetic data relating to carbamazepine and oxcarbazepine trials were collected in 1141 patients. We did not observe any genome-wide significant associations with sodium level in a linear trend or hyponatremia as a dichotomous trait. Age, sex, number of comedications, phenytoin use, phenobarbital use, and sodium valproate use were significant predictors of CBZ metabolic ratio. No genome-wide significant associations with CBZ metabolic ratio were found. Significance: Although we did not detect a genetic predictor of hyponatremia or CBZ metabolism in our cohort, our findings suggest that the determinants of CBZ metabolism are multifactorial. |